Trial Profile
Phase I trial of SCY 635 in patients with genotype 1 hepatitis C.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Apr 2010
Price :
$35
*
At a glance
- Drugs SCY 635 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors SCYNEXIS
- 16 Apr 2010 Resistance results presented at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL), according to a SCYNEXIS media release.
- 26 Apr 2009 Results reported at the 44th Annual Meeting of the European Association for the Study of the Liver.
- 25 Apr 2009 Results were presented in a media release, and at the 44th Annual Meeting of the European Association for the Study of the Liver.